（记者 张明双） 每经头条（nbdtoutiao）——白银50天涨逾80%，疯狂程度远超黄金，历史上爆炒白银往往预示贵金属 牛市已到高潮，这次有何不同？ 每经AI快讯，益方生物1月16日晚间发布公告称，公司限售股份约1.61亿股将于2026年1月26日解禁并上 市流通，占公司总股本比例为27.79%。 ...

Group 1 - Watson Bio announced that its fifth board meeting was held on January 16, 2026, via telecommunication voting, where it reviewed the rectification report regarding the corrective measures ordered by the Yunnan Securities Regulatory Bureau [1] Group 2 - Silver prices have surged over 80% in the last 50 days, indicating a level of speculation that surpasses that of gold, suggesting that the current silver market frenzy may signal a peak in the precious metals bull market [1]

以下文章来源于虎嗅APP ，作者董必政 虎嗅APP . 从思考，到创造 导读： 港股IPO热闹非凡。 作者｜董必政 来源 ｜虎嗅APP 2026年的开年大戏，不在大银幕，而在港交所的锣声里。 仅仅过去不到半个月，港股IPO市场就热闹非凡。1月2日，"港股GPU第一股"壁仞科技首日暴涨 94.59%。 紧接着，1月8日，精锋医疗-B、天数智芯、智谱华章三家硬科技企业同日挂牌。1月9日，瑞博生 物、MiniMax接力登场。就在这短短几天内，GPU、大模型、生物科技在港股纷纷上市。 甚至连那久违的"千倍认购"神话，都随着智谱和MiniMax的招股重现江湖。 真正让这些企业夜不能寐的，是账上的现金流。 AI又是一场极度"烧钱"的行业。而资本市场不仅是交易所，更是AI企业的弹药库。 翻开招股书，我们可以发现2025年上半年，壁仞亏损16亿，智谱亏损23.6亿，天数智芯亏损6.1 亿。 以智谱为例，这家大模型企业每个月的研发支出高达2.66亿元。而截至上市前，其账面现金仅剩 25.5亿元。如果不上市输血，这笔钱只能撑9个月。 天数智芯更夸张，其研发费率高达139%，也就是每挣1块钱，就要花1.4元去搞研发。 那为何又是港 ...

Core Viewpoint - The company focuses on innovative treatments for mature targets, aiming to differentiate itself in the competitive PD-(L)1 market, particularly with its PD-1 monoclonal antibody, which is set to be the first and only approved treatment for ES-SCLC in the EU by February 2025 [1] Group 1: Innovative Drug Pipeline - The PD-1 monoclonal antibody is targeting small cell lung cancer as a core differentiation track while also expanding into new indications, potentially becoming the first immunotherapy approved for perioperative gastric cancer and first-line colorectal cancer [1] - HLX07, an engineered EGFR monoclonal antibody, has an extended half-life allowing for a three-week dosing schedule alongside H drug, showing excellent efficacy and safety in treating refractory squamous non-small cell lung cancer [1] - HLX43, a PD-L1 ADC with a dual toxin release mechanism, has shown superior anti-tumor efficacy and manageable safety in Phase I trials, with multiple Phase II trials for mainstream cancers like non-small cell lung cancer and liver cancer poised to start [1] Group 2: Biosimilar Drug Pipeline - The company has a long-standing commitment to the biosimilar drug sector and is advancing its global strategy, with HLX14 (dexamethasone) already approved in Europe and the US, and HLX11 (pertuzumab) approved in the US with applications pending in China and Europe [2] - The pipeline also includes targets like CTLA-4 and CD38, with ongoing overseas clinical studies to support global market expansion [2] Group 3: Financial Forecast - The company anticipates continued revenue contributions from its biosimilar drugs and accelerated innovation drug development, projecting revenues of 6.009 billion, 5.999 billion, and 6.438 billion yuan for 2025-2027, with net profits of 798 million, 804 million, and 839 million yuan respectively, corresponding to PE ratios of 47, 46, and 45 times [2]

Core Viewpoint - The company has received a notification from the China Securities Regulatory Commission (CSRC) regarding the registration of the "full circulation" of its unlisted shares, indicating progress towards H-share full circulation [1] Group 1: Company Actions - The company has completed the registration with the CSRC for the full circulation of 183 million unlisted shares held by certain shareholders [1] - The company must complete the H-share full circulation conversion and listing within 12 months from the date of the notification, or it will need to update the registration materials with the CSRC [1]

Core Viewpoint - The company has developed an mRNA vaccine for shingles, which has received acceptance for clinical trial application from the National Medical Products Administration [1] Group 1 - The company's wholly-owned subsidiary, Zhifei Longkema, is responsible for the research and development of the shingles mRNA vaccine [1] - The clinical trial application for the shingles mRNA vaccine has been officially accepted, indicating progress in the vaccine's development [1]

Core Viewpoint - I-Well Bio (300357) has announced the completion of a Phase I clinical trial for its "house dust mite film agent," demonstrating safety and tolerability in adult patients with dust mite allergic rhinitis [1] Group 1: Clinical Trial Details - The clinical trial was randomized, double-blind, placebo-controlled, and involved dose escalation [1] - The study evaluated various maintenance doses ranging from 150 BU to 2700 BU, all of which are deemed suitable for Phase II clinical research [1] - Researchers plan to further explore the efficacy and safety of these doses by extending the administration period and increasing the sample size [1]

Group 1 - The core objective of the "Implementation Plan for Accelerating the Cultivation of R&D Enterprises and Promoting R&D Industrialization" is to strengthen the innovation role of enterprises and support the establishment of a nationally influential technology innovation center in Wuhan by 2027 [1] - By 2027, the plan aims to establish 30 city-level concept verification centers, 200 pilot test platforms, and exceed 1,200 city-level enterprise R&D centers, with over 300 R&D enterprises and more than 30 foreign-funded R&D centers [1][2] - The plan emphasizes the creation of 3-5 R&D industrial clusters in key sectors such as optoelectronic information, health, and biotechnology [1] Group 2 - The plan includes a "Seedling Plan" for startups, providing up to 500,000 yuan in R&D support for selected high-growth enterprises over three years, and rewards for high-tech enterprises upon initial and re-certification [2] - For leading enterprises, the "Gazelle Plan" and "Leading Plan" offer annual R&D subsidies of 300,000 yuan and support for establishing industry innovation joint laboratories with a total funding of 20 million yuan per year for three years [2] - The plan also proposes that R&D institutions within enterprises can register as independent legal entities, receiving up to 5 million yuan annually for three years based on their incremental R&D investment [2] Group 3 - The plan provides rewards of up to 1 million yuan for enterprises purchasing technological achievements and accelerates the construction of verification centers and pilot platforms in cutting-edge fields like quantum technology and advanced semiconductors [3] - It emphasizes the importance of talent, finance, and intellectual property protection, offering various support measures for innovative talent, including housing guarantees, project support, financial rewards, and housing subsidies [3]

Core Viewpoint - Antu Biology (603658.SH) announced that its wholly-owned subsidiary, Zhengzhou Sikun Biological Engineering Co., Ltd., and its secondary subsidiary, Zhengzhou Matris Biological Technology Co., Ltd., have recently received the "High-tech Enterprise Certificate" from the Henan Provincial Department of Science and Technology, Henan Provincial Department of Finance, and the State Taxation Administration of Henan Province, marking their recognition as high-tech enterprises [1] Group 1 - The subsidiaries received their high-tech enterprise certifications for the first time [1] - The certificate numbers are GR202541001506 and GR202541001407, with both issued on November 4, 2025, and valid for three years [1]

Core Viewpoint - The company has received approval from the China Securities Regulatory Commission for the conversion of approximately 182.6 million unlisted shares into H-shares for full circulation, which is a significant step towards enhancing its market presence and liquidity [1] Group 1: Regulatory Approval - The company has completed the filing for the conversion of about 182.6 million unlisted shares into H-shares for full circulation [1] - If the conversion and listing are not completed within 12 months from the issuance date, the company will need to update its filing materials with the China Securities Regulatory Commission to continue the process [1] Group 2: Strategic Development - The company showcased its "Globalization 2.0" strategy at the JPM 2026 conference, outlining its future innovation pipeline and development plans [1] - Over the next five years, the company anticipates more than 40 new clinical research applications to be approved [1] - By 2030, the company expects to have over 20 products launched globally, with 15 of them likely to enter the European and American markets [1] Group 3: Product Pipeline and Market Focus - The company plans to commercialize more Antibody-Drug Conjugates (ADCs), bispecific antibodies, and T-cell engagers (TCEs) across four major therapeutic areas: oncology, autoimmune diseases, metabolism, and central nervous system disorders [1] - With the enhancement of its global commercialization capabilities, the company is poised for further growth in overseas revenue, solidifying its foundation as an international biopharmaceutical company [1] Group 4: Market Performance - As of January 16, the company's stock has increased by 19.63% since the beginning of the year and has seen a 194.18% increase over the past 250 days [1] - The total market capitalization of the company stands at 37.1 billion Hong Kong dollars [1]